Pharmacy-Based Methadone Dispensing Could Turn Profit While Expanding Treatment Access, Study Finds

Integrating methadone treatment for opioid use disorder into community pharmacies could expand access to life-saving medication while generating substantial profits for struggling retail pharmacy operations, according to a first-of-its-kind economic analysis published March 16 in JAMA Network Open.

The Brandeis University-led study evaluated two pharmacy-based methadone dispensing models and found both generate positive returns on investment over three years—challenging assumptions that extending methadone beyond federally certified opioid treatment programs would burden pharmacies already facing closure pressures nationwide.

Under a "medication unit" model, where existing opioid treatment programs extend services to pharmacies serving as satellite dispensing locations, researchers projected pharmacies would earn $3.53 for every dollar spent, netting $96,904 in profit over three years and reaching $150,000 by year three.

A "pharmacist-dispensed" model—in which DEA-registered medical providers prescribe methadone directly dispensed by pharmacists—returned $2.64 per dollar, generating $23,844 in net profit over three years.

"Frankly, we were surprised that both scenarios generated such high return on investment, which bodes well for policymakers who want to increase access to treatment while at the same time supporting local businesses," said Cynthia A. Tschampl, research scientist at Brandeis' Heller School for Social Policy and Management and lead author of the study.

Treatment Deserts and Pharmacy Closures Create Parallel Crises

The findings arrive as two trends collide: treatment deserts leaving most Americans without methadone access, and independent pharmacies closing at accelerating rates especially in rural and low-income communities.

Approximately 2,100 federally certified opioid treatment programs operate nationwide, but 80% of U.S. counties—including the entire state of Wyoming—lack even a single facility. Methadone, a synthetic opioid used since the 1960s to reduce cravings and withdrawal, can currently be administered or dispensed only through these federally regulated programs, with rare exceptions.

The geographic mismatch forces people with opioid use disorder to travel hours for daily dosing during initial treatment phases, creating insurmountable barriers for those lacking transportation, facing work or childcare demands, or living in areas where no program exists within reasonable distance.

Meanwhile, retail pharmacies face mounting financial pressures. Closures have disproportionately affected independent pharmacies and those serving rural areas—the same communities most desperate for expanded methadone access.

"Pharmacies are struggling financially," said Jeffrey Bratberg, University of Rhode Island College of Pharmacy professor and co-investigator. "If a pharmacy is your only choice for access to a medication and they go out of business, you lose all access to all medications. Our findings show offering methadone in pharmacies does not have that risk."

Two Pathways Forward Under Current and Expanded Regulations

The study, supported by The Pew Charitable Trusts, analyzed distinct regulatory and operational scenarios for pharmacy integration.

The medication unit model operates within current federal law. Established opioid treatment programs can designate pharmacies as satellite dispensing locations, extending their existing certification to community pharmacies where patients pick up prescribed doses. This model produced the higher return—$3.53 per dollar—because pharmacies leverage existing OTP infrastructure, clinical oversight, and billing relationships while adding a profitable service line.

The pharmacist-dispensed model would require regulatory interpretation changes by the Drug Enforcement Administration. Under this approach, DEA-registered prescribers write methadone prescriptions filled by pharmacists just as they dispense buprenorphine or naltrexone today. Though generating lower returns ($2.64 per dollar), this model would dramatically simplify access by eliminating the need for formal OTP certification and allowing methadone to enter the same prescribing-dispensing pathway used for other medications.

Researchers surveyed stakeholders including methadone patients, opioid treatment program operators, public and private payers, and state and federal policymakers to build realistic cost and revenue assumptions.

Context of National Overdose Decline and Access Expansion Momentum

The study's publication follows encouraging national trends. Opioid overdose deaths in the United States have declined more than 28% recently, representing the steepest sustained drop recorded during the long overdose crisis.

"We've seen an over-28% reduction in overdose deaths recently in the U.S, which is encouraging," said Traci Green, professor and director of the Opioid Policy Research Collaborative at Brandeis and senior author. "We need accessible medication treatment with methadone to support people, not only to help them survive but to set them up to thrive. It doesn't get more accessible than your local pharmacy, and this study shows that's not just a logistical advantage for patients, but also a financial one for pharmacists."

The decline has been attributed in part to increased naloxone availability, expanded access to medications for opioid use disorder including buprenorphine, and harm reduction programs reaching marginalized populations. Yet methadone—the oldest and in many cases most effective medication for opioid use disorder—remains locked behind regulatory barriers limiting its reach.

Financial Viability Removes Key Implementation Barrier

Economic uncertainty has stalled pharmacy-based methadone initiatives even where regulatory pathways exist. Pharmacy owners facing razor-thin margins hesitate to invest in infrastructure, training, and security measures without confidence in financial sustainability.

"It is a disservice to your patient if you start something and later say 'I can't keep doing this because it's not financially viable,'" Bratberg noted.

The study's positive return projections across both models provide the economic evidence needed for pharmacies to make informed expansion decisions. Researchers constructed three-year financial models accounting for startup costs (security infrastructure, staff training, inventory management systems), ongoing operational expenses (staffing, medication procurement, compliance), and projected revenue streams (medication reimbursement, clinical service fees, patient volume).

Both models assumed modest patient panels—realistic for community pharmacies rather than high-volume treatment centers. Even at conservative volume estimates, returns remained strongly positive, suggesting pharmacy-based methadone could serve smaller populations in rural areas while remaining financially viable.

Policy Implications and Implementation Challenges

The medication unit model's higher returns reflect simpler integration. Existing opioid treatment programs already navigate federal certification, provide counseling and clinical oversight, manage complex billing, and maintain security protocols. Extending services to pharmacy satellites leverages this infrastructure while pharmacies focus on secure dispensing—a core competency.

Pharmacist-dispensed methadone faces steeper implementation hurdles despite current use of the model for buprenorphine. DEA regulations classify methadone differently, requiring more restrictive handling. Expanding the pharmacist-dispensed model would need regulatory reinterpretation or legislative changes—a politically fraught process given ongoing debates about controlled substance access, diversion risks, and scope of pharmacy practice.

Yet the model's promise lies in scalability. If DEA allowed methadone prescribing and dispensing through standard pharmacy channels, the nation's 60,000-plus retail pharmacies could theoretically offer methadone wherever demand exists—instantly transforming treatment access in rural counties, small towns, and underserved urban neighborhoods currently traveling hours to the nearest federally certified program.

Addressing Stigma and Normalizing Care

Beyond dollars and regulations, pharmacy integration addresses the less quantifiable but equally important barrier of stigma. Methadone patients often describe feeling marked when visiting specialized opioid treatment programs, facing judgmental attitudes from staff or community members who associate the facilities with criminal justice and active drug use rather than chronic disease management.

Picking up methadone at a neighborhood pharmacy—alongside people collecting insulin, blood pressure medications, or antibiotics—normalizes opioid use disorder treatment as medical care rather than moral failure. The study notes that people with opioid use disorder need treatment options that are "more accessible, convenient, and normalized."

Pharmacies are already trusted healthcare access points, particularly in medically underserved areas where they may represent the only local healthcare presence. Pharmacists frequently serve as first-line healthcare advisors, managing chronic disease medications, providing immunizations, and connecting patients to additional services. Integrating methadone treatment aligns with this expanded pharmacy role.

Next Steps: From Evidence to Implementation

The research team included Elena Soranno, an undergraduate research assistant at the Heller School; Murray Dawson, a graduate research assistant at the Heller School; Sage Feltus, a research associate; and Maureen T. Stewart, research associate professor at Boston University School of Public Health.

Translating the study's findings into operational programs requires coordination among federal regulators (DEA, SAMHSA, CMS), state pharmacy and medical boards, payers negotiating reimbursement rates, opioid treatment programs willing to extend satellite services, and pharmacies committing to infrastructure investments.

Several states have begun pilot initiatives testing medication unit models in underserved areas. California, for example, recently passed legislation supporting pharmacy-based methadone dispensing under opioid treatment program oversight in counties lacking sufficient access.

The pharmacist-dispensed model remains largely theoretical pending regulatory changes, though advocacy organizations argue the COVID-19 pandemic's temporary methadone take-home flexibilities demonstrated that loosening restrictions did not trigger predicted increases in diversion or overdose deaths—building evidence for permanent regulatory reform.

For struggling retail pharmacies searching for sustainable revenue streams as prescription reimbursements decline and pharmacy benefit managers squeeze margins, methadone treatment represents a rare opportunity: a profitable service line addressing a desperate public health need with strong community support and stable long-term demand.

For the hundreds of thousands of Americans living with opioid use disorder in counties without methadone access—especially in rural areas where program deserts and pharmacy closures overlap—the study offers hope that effective treatment could soon be as close as the corner pharmacy.

"We need to make methadone more accessible," Green emphasized. "Pharmacies are where people already go for healthcare. If we can bring methadone there, and it works financially, we remove major barriers that have kept life-saving treatment out of reach for too many Americans for too long."